Published in Clin Cancer Res on August 15, 2004
Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17
Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res (2009) 3.76
To differentiate or not--routes towards metastasis. Nat Rev Cancer (2012) 3.59
Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer (2009) 3.49
A "class action" against the microenvironment: do cancer cells cooperate in metastasis? Cancer Metastasis Rev (2008) 1.91
Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res (2009) 1.78
The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat (2012) 1.77
Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res (2012) 1.62
Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br J Cancer (2008) 1.34
ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res (2008) 1.24
Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Br J Cancer (2009) 1.24
APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. J Cell Biochem (2008) 1.18
Disseminated breast cancer cells acquire a highly malignant and aggressive metastatic phenotype during metastatic latency in the bone. PLoS One (2012) 1.15
Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res (2013) 1.15
Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance. Breast Cancer Res (2008) 1.09
Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. Breast Cancer Res (2009) 1.06
Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Res (2012) 1.00
Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer. Breast Cancer Res (2006) 0.99
Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. Breast Cancer Res (2011) 0.99
Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues. J Clin Pathol (2007) 0.99
Circulating tumor cells in breast cancer patients: an evolving role in patient prognosis and disease progression. Patholog Res Int (2011) 0.94
Delineation of breast cancer cell hierarchy identifies the subset responsible for dormancy. Sci Rep (2012) 0.92
A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype. Breast Cancer Res (2014) 0.90
Detection of disseminated tumor cells in the bone marrow of breast cancer patients using multiplex gene expression measurements identifies new therapeutic targets in patients at high risk for the development of metastatic disease. Breast Cancer Res Treat (2012) 0.89
Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome. BMC Cancer (2012) 0.84
Circulating tumour cells in breast cancer. Ecancermedicalscience (2013) 0.84
Time to metastatic relapse and breast cancer cells dissemination in bone marrow at metastatic relapse. Clin Exp Metastasis (2008) 0.82
Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study. BMC Cancer (2012) 0.81
Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor? J Cancer Res Clin Oncol (2005) 0.80
Detection of disseminated tumor cells in bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancer. J Cancer Res Clin Oncol (2014) 0.79
Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. Breast Cancer Res (2014) 0.79
Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. Integr Biol (Camb) (2014) 0.79
Cytokeratin-positive cells in the bone marrow of breast cancer patients and noncancer donors. Appl Immunohistochem Mol Morphol (2009) 0.78
SMAD signaling and redox imbalance cooperate to induce prostate cancer cell dormancy. Cell Cycle (2015) 0.77
Skeletal manifestations of treatment of breast cancer. Curr Osteoporos Rep (2013) 0.77
Non-migratory tumorigenic intrinsic cancer stem cells ensure breast cancer metastasis by generation of CXCR4(+) migrating cancer stem cells. Oncogene (2016) 0.77
Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients. Breast Cancer Res (2009) 0.76
Vascular damage and anti-angiogenic effects of tumor vessel-targeted adenovirus-mediated herpes simplex virus thymidine kinase gene. World J Gastroenterol (2007) 0.76
Approaches to isolation and molecular characterization of disseminated tumor cells. Oncotarget (2015) 0.76
The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy. Breast Cancer Res (2013) 0.76
Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial. BMC Cancer (2016) 0.75
Could cancer initiate from bone marrow progenitors? Iran J Cancer Prev (2013) 0.75
Comparison of molecular and immunocytochemical methods for detection of disseminated tumor cells in bone marrow from early breast cancer patients. BMC Cancer (2014) 0.75
Non-invasive real-time biopsy of intracranial lesions using short time expanded circulating tumor cells on glass slide: report of two cases. BMC Neurol (2016) 0.75
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature (2005) 18.30
Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A (2010) 7.70
A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86
Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res (2006) 4.25
Mutation of GATA3 in human breast tumors. Oncogene (2004) 3.92
Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell (2004) 3.73
Morphologic reappraisal of serrated colorectal polyps. Am J Surg Pathol (2003) 3.59
Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer (2005) 3.26
TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res (2007) 3.01
Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics (2006) 2.86
miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One (2011) 2.70
High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol (2003) 2.65
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol Oncol (2007) 2.06
Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology (2009) 1.91
EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol (2002) 1.86
A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer (2006) 1.82
Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A (2011) 1.78
Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res (2005) 1.59
Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis. Clin Cancer Res (2011) 1.56
Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients. Genes Chromosomes Cancer (2008) 1.54
Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development. Cancer Res (2005) 1.52
Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol (2010) 1.44
DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer (2007) 1.44
Circulating and disseminated tumor cells. J Clin Oncol (2005) 1.43
Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res (2009) 1.41
Expression of Ephb2 and Ephb4 in breast carcinoma. Pathol Oncol Res (2004) 1.41
CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression. Mod Pathol (2004) 1.38
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med (2013) 1.38
Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int J Cancer (2006) 1.33
DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables. Mol Oncol (2010) 1.33
Genes harbouring susceptibility SNPs are differentially expressed in the breast cancer subtypes. Breast Cancer Res (2007) 1.30
Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma. Clin Cancer Res (2003) 1.26
Nuclear localization of the metastasis-related protein S100A4 correlates with tumour stage in colorectal cancer. J Pathol (2003) 1.23
Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother (2006) 1.23
Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses. Mol Cancer (2007) 1.23
Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors. Cancer Res (2003) 1.21
Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines. PLoS One (2013) 1.17
The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol (2002) 1.16
The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma. Int J Gynecol Pathol (2007) 1.16
Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med (2002) 1.15
5-Aminolevulinic acid-based photodynamic detection and therapy of brain tumors (review). Int J Oncol (2002) 1.15
Radiation-induced sarcoma: 25-year experience from the Norwegian Radium Hospital. Acta Oncol (2008) 1.14
Expression of HIWI in human esophageal squamous cell carcinoma is significantly associated with poorer prognosis. BMC Cancer (2009) 1.13
Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling. Int J Radiat Oncol Biol Phys (2010) 1.13
Pilomatrix carcinoma with lymph node metastases. J Cutan Pathol (2004) 1.12
Physical activity for the affected limb and arm lymphedema after breast cancer surgery. A prospective, randomized controlled trial with two years follow-up. Acta Oncol (2009) 1.11
Combining gene signatures improves prediction of breast cancer survival. PLoS One (2011) 1.11
Expression of non-membranous beta-catenin and gamma-catenin, c-Myc and cyclin D1 in relation to patient outcome in human colon adenocarcinomas. APMIS (2004) 1.10
Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern. Breast Cancer Res Treat (2010) 1.09
The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol Oncol (2005) 1.09
The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer (2012) 1.09
The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma. Gynecol Oncol (2006) 1.09
Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother (2013) 1.08
Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination. Clin Cancer Res (2008) 1.07
[Re: An integrated understanding of subjective disorders in clinical practice]. Tidsskr Nor Laegeforen (2015) 1.07
The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients. Breast Cancer Res (2011) 1.07
The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells. Clin Cancer Res (2004) 1.07
Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis. Genome Biol (2014) 1.07
beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients. Eur J Cancer (2005) 1.06
NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations. Mol Cancer (2010) 1.06
Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. J Clin Oncol (2003) 1.06
Prostate cancer cell lines under hypoxia exhibit greater stem-like properties. PLoS One (2011) 1.05
Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res (2003) 1.05
Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma. Gynecol Oncol (2004) 1.03
The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol (2006) 1.03
High-resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer. Int J Cancer (2011) 1.02
Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination. Cancer Gene Ther (2005) 1.02
Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome. Oncol Rep (2010) 1.02
Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat (2004) 1.01
Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells. Clin Cancer Res (2006) 1.00
Changes in arm morbidities and health-related quality of life after breast cancer surgery - a five-year follow-up study. Acta Oncol (2009) 1.00
Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. Int J Cancer (2007) 1.00
Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Res (2012) 1.00